Two class 1.1 heavyweight new drugs of synthetic pharmaceutical industry settled in China Pharmaceutical City

On February 23, 2016, major innovation projects of Synthetic Medicine (832077) were successfully signed and settled in China Pharmaceutical city According to reports, Shaanxi Synthetic Pharmaceutical Co., Ltd plans to invest 400 million yuan to establish Tiandi human and Biotechnology Co., Ltd in China Pharmaceutical city to engage in the research and development, registration and application, clinical trials, production and sales of class 1 new drugs At present, the company has successfully developed two class 1.1 heavy-duty new drugs, one is levonorgestrel disodium phosphate for injection, which is a new type of anti anaerobe infection drug, and has obtained the approval document for drug clinical trial issued by the State Food and Drug Administration in June 2015; the other is hcp002, which is a new type of anti fungus drug, and has completed the preparation of the certificate It is expected that The clinical trial approval was obtained in March 2016 It is reported that the two new drugs of category 1.1 have entrusted cro Nanjing Maituo Pharmaceutical Technology Co., Ltd to start clinical trials in March and April this year This successful settlement represents the industrialization of these two class 1.1 new drugs in China Pharmaceutical City, Taizhou City, Jiangsu Province Yang Cheng, chairman and general manager of Shaanxi Synthetic Pharmaceutical Co., Ltd is expected to reach 1 billion yuan in annual sales and 2 billion yuan in annual sales after putting into production It is understood that Tian Di Ren He Biotechnology Co., Ltd will acquire 80 mu of land in China Pharmaceutical city and build a base integrating R & D, production and sales It is expected that infrastructure construction will be completed in 2017 and production will be fully achieved in 2019 About Synthetic Medicine Shaanxi Synthetic Pharmaceutical Co., Ltd was founded in 2014, which was changed from the overall restructuring of Shaanxi Synthetic Pharmaceutical Co., Ltd established in April 2009 The company was successfully listed in the national small and medium-sized enterprise stock transfer system in March 2015 (Stock Name: synthetic pharmaceutical industry; Stock Code: 832077) It is a new drug technology enterprise dedicated to drug research and development, registration and application The scope of research and development involves all kinds of new chemical drugs, and structural modification is carried out for the drug defects currently on the market, so as to independently develop new chemical drugs with stronger efficacy and higher safety At present, it has Taizhou R & D center of synthetic pharmaceutical industry and subsidiary of Jiangsu tiandirenhe Pharmaceutical Co., Ltd Based on the concept of "preciseness, pragmatism, innovation and progress", the company has established a complete new drug project R & D system with a process management system of information collection, project approval, R & D and application of new drug projects Synthetic pharmaceutical industry is a high-tech enterprise jointly recognized by the Department of science and technology, the Department of Finance and the tax bureau of Shaanxi Province And won the most innovative domestic enterprises and China's top 10 pharmaceutical innovation ability enterprises in 2014 China drug review list About China Pharmaceutical City China Pharmaceutical City, located in Taizhou, an important member city of the Yangtze River Delta, with an overall planning area of 30 square kilometers, is composed of scientific research and Development Zone, production and manufacturing zone, exhibition and Trade Zone, health and Medical Zone, education and Teaching Zone, comprehensive supporting zone and other functional zones It is the first national pharmaceutical High-tech Zone in China, which is composed of the Ministry of science and technology, the national health and Family Planning Commission, and the State Food and drug administration State Administration of traditional Chinese medicine and Jiangsu Provincial People's government Since the start of the construction of China Pharmaceutical City, in accordance with the planning and construction concept of "invigorating the city with industry, promoting the city with industry, integrating industry and city, and sharing prosperity with industry and city", we have been committed to building a biomedical industry base with the largest scale and the most complete industrial chain in China At present, more than 50 well-known universities and pharmaceutical R & D institutions at home and abroad have gathered in the area, more than 440 well-known pharmaceutical enterprises at home and abroad, such as AstraZeneca, Takeda pharmaceutical, bringer ingelham, Shiyao group, and Haiwang pharmaceutical, have successively settled down; more than 400 "first-class international and domestic leading" pharmaceutical innovation achievements have been successfully applied; more than 1730 high-level talents at home and abroad have settled down and started businesses, 26 people Selected into the national "thousand talents plan"; about Maituo medicine Nanjing Maituo Pharmaceutical Technology Co., Ltd (hereinafter referred to as "Maituo pharmaceutical") is a high-tech company specialized in providing clinical trial cro and clinical scientific research information solutions for medical institutions, pharmaceutical enterprises and scientific research institutions It is committed to providing all participants in clinical trials with the most advanced tools to plan and manage clinical trials, so as to make their development cycle shorter and risk smaller , lower cost and create value for customers Maituo pharmaceutical is committed to accelerating the development of new drugs and clinical trials, including clinical trial cro, clinical trial management system, new drug technology informatization and medical information engineering research At present, Maxtor pharmaceutical has the leading farmer in China Gamma At the same time, the company has a new drug technology transfer platform: new drug collection (www.xinyaohui Com) Maituo pharmaceutical has established strategic cooperation with many hospitals and pharmaceutical enterprises [copyright notice: This is the exclusive report of new drug collection Please indicate the source for reprint]